Jin Pyo Hong MD, PhD, Akramul Zikri Abd Malek MBBS, Dr (Psych), Cheng-Ta Li MD, PhD, Jong-Woo Paik MD, PhD, Ahmad Hatim Sulaiman MBBS, MPM, PhD, Gilbert Madriaga DPT, MSc, Jianmin Zhuo PhD, Sarah Siggins PhD, Dong-Jing Fu MD, PhD, Po-Chung Ju PhD
{"title":"除标准护理外，艾司他明鼻喷雾剂对有主动自杀意念的重度抑郁症患者的疗效和安全性：ASPIRE I亚洲队列的亚组分析（一项随机、双盲、安慰剂对照研究）。","authors":"Jin Pyo Hong MD, PhD, Akramul Zikri Abd Malek MBBS, Dr (Psych), Cheng-Ta Li MD, PhD, Jong-Woo Paik MD, PhD, Ahmad Hatim Sulaiman MBBS, MPM, PhD, Gilbert Madriaga DPT, MSc, Jianmin Zhuo PhD, Sarah Siggins PhD, Dong-Jing Fu MD, PhD, Po-Chung Ju PhD","doi":"10.1111/appy.12548","DOIUrl":null,"url":null,"abstract":"<p>This post-hoc analysis evaluated the efficacy and safety of intranasal esketamine in the Asian subgroup from ASPIRE I. Patients with major depressive disorder and suicidal ideation with intent received intranasal esketamine (<i>n</i> = 26) or placebo (<i>n</i> = 27), plus standard of care for 25 days. The primary endpoint was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to Day 2. The MADRS score improved in favor of esketamine (least squares mean difference: −3.8). No unexpected safety concerns were noted. The Asian subgroup showed a similar efficacy and safety profile as the total ASPIRE I cohort.</p>","PeriodicalId":8618,"journal":{"name":"Asia‐Pacific Psychiatry","volume":"15 4","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of ASPIRE I (a randomized, double-blind, placebo-controlled study)\",\"authors\":\"Jin Pyo Hong MD, PhD, Akramul Zikri Abd Malek MBBS, Dr (Psych), Cheng-Ta Li MD, PhD, Jong-Woo Paik MD, PhD, Ahmad Hatim Sulaiman MBBS, MPM, PhD, Gilbert Madriaga DPT, MSc, Jianmin Zhuo PhD, Sarah Siggins PhD, Dong-Jing Fu MD, PhD, Po-Chung Ju PhD\",\"doi\":\"10.1111/appy.12548\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>This post-hoc analysis evaluated the efficacy and safety of intranasal esketamine in the Asian subgroup from ASPIRE I. Patients with major depressive disorder and suicidal ideation with intent received intranasal esketamine (<i>n</i> = 26) or placebo (<i>n</i> = 27), plus standard of care for 25 days. The primary endpoint was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to Day 2. The MADRS score improved in favor of esketamine (least squares mean difference: −3.8). No unexpected safety concerns were noted. The Asian subgroup showed a similar efficacy and safety profile as the total ASPIRE I cohort.</p>\",\"PeriodicalId\":8618,\"journal\":{\"name\":\"Asia‐Pacific Psychiatry\",\"volume\":\"15 4\",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2023-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asia‐Pacific Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/appy.12548\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia‐Pacific Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/appy.12548","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of ASPIRE I (a randomized, double-blind, placebo-controlled study)
This post-hoc analysis evaluated the efficacy and safety of intranasal esketamine in the Asian subgroup from ASPIRE I. Patients with major depressive disorder and suicidal ideation with intent received intranasal esketamine (n = 26) or placebo (n = 27), plus standard of care for 25 days. The primary endpoint was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to Day 2. The MADRS score improved in favor of esketamine (least squares mean difference: −3.8). No unexpected safety concerns were noted. The Asian subgroup showed a similar efficacy and safety profile as the total ASPIRE I cohort.
期刊介绍：
Asia-Pacific Psychiatry is an international psychiatric journal focused on the Asia and Pacific Rim region, and is the official journal of the Pacific Rim College of Psychiatrics. Asia-Pacific Psychiatry enables psychiatric and other mental health professionals in the region to share their research, education programs and clinical experience with a larger international readership. The journal offers a venue for high quality research for and from the region in the face of minimal international publication availability for authors concerned with the region. This includes findings highlighting the diversity in psychiatric behaviour, treatment and outcome related to social, ethnic, cultural and economic differences of the region. The journal publishes peer-reviewed articles and reviews, as well as clinically and educationally focused papers on regional best practices. Images, videos, a young psychiatrist''s corner, meeting reports, a journal club and contextual commentaries differentiate this journal from existing main stream psychiatry journals that are focused on other regions, or nationally focused within countries of Asia and the Pacific Rim.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
